Lupin launches Sevelamer Hydrochloride Tablets in the United States; Stock dips 1%

2 Mar 2022 , 11:15 AM

Global pharma major Lupin Limited (Lupin) on Tuesday announced the launch of Sevelamer Hydrochloride Tablets, 800 ms, having received approval from the United States Food and Drug Administration (FDA).

The product will be manufactured at Lupin’s facility in Nagpur, India.

The company said in a regulatory filing that Sevelamer Hydrochloride Tablets, 800 mg is a generic equivalent of Renagel Tablets, 800 mg of Genzyme Corporation.

Sevelamer Hydrochloride Tablets, 800 mg (RLD: Renagel) had estimated annual sales of USO 75 million in the U.S. (IQVIA MAT December 2021).

At around 11.16 am, Lupin Ltd was trading at Rs738.25 per piece down by Rs7.45 or 1% from its previous closing of Rs745.70 per piece on the BSE. The scrip opened at Rs743 and has touched a high and low of Rs749.10 and Rs733.60 respectively.